The programmed death-1/programmed death ligand 1 (PD-1/PD-L1) axis of interaction is one of the most important immunosuppressive mechanisms within the tumor microenvironment (TME), and targeting this mechanism has led to exciting therapeutic advances in clinical oncology (1–6). Here, CD274 is linked to neoplasm.